drugset / Trial / NCT02102932
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of Empagliflozin and metformin compared to the administration of single tablets (Empagliflozin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patient's compliance with antidiabetic treatment, in particular with concern to the frequent polypharmacy in diabetic patients.
Timeline
- Start
- 2014-05
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 5 mg | — |
| Subject | Empagliflozin | Small molecule | 12.5 mg | — |
| Subject | Metformin | Small molecule | 500 mg | — |
| Subject | Metformin | Small molecule | 850 mg | — |
Indications
No indication recorded.